Healthcare
Live Price
Offline$1.35
+0.00% today
Window Change
-19.16%
Window
May 29, 2026 โ Jun 24, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 19 bars ยท May 29, 2026 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ascletis Pharma Inc. (ASCLF) is a Healthcare stock with a market cap of $15.37B. The stock last traded around $1.35 and down 19.2% across the available one-year price window (May 29, 2026 โ Jun 24, 2026). Baseline metrics include revenue growth of +54.0%, EPS growth of -20.0%, a dividend yield of 0.0%. What stands out right now is revenue +54.0%, EPS -20.0%, free cash flow +3.7% with operating margin -23797.7% and ROIC -24.6%. Valuation already assumes a fairly strong business story at price/sales 7636.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ASCLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+54.0% vs +7.6% peer median
Operating Margin
Below sector median
-23797.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
Q1 2026 was reported on Mar 13, 2026 with an EPS surprise of +5.3%.
The operating picture looks softer than before
Revenue is at +54.0% and EPS is at -20.0%, with operating margin around -23797.7%.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ASCLF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ASCLF Max Drawdown
-20.96%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for ASCLF and SPY.
Company Overview
Ascletis Pharma Inc.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.